Jacobs Retina Center, Department of Ophthalmology, University of California at San Diego, La Jolla, USA.
Am J Ophthalmol. 2010 Jul;150(1):63-67.e1. doi: 10.1016/j.ajo.2010.01.039. Epub 2010 May 10.
PURPOSE: To evaluate the integrity of the photoreceptor inner segment/outer segment (IS/OS) junction using spectral-domain optical coherence tomography (SD OCT) in patients with diabetic macular edema and to correlate the relationship between the integrity of the IS/OS junction and visual acuity. DESIGN: Retrospective, comparative, consecutive case series. METHODS: Sixty-two eyes from 38 patients with diabetic macular edema underwent SD OCT imaging. For each patient, 2 experienced observers masked to visual acuity measured several SD OCT variables, including central macular thickness, retinal volume, global disruption scale of outer retina, percentage disruption of the outer retina, and history of previous treatments. Visual acuity recorded as number of Early Treatment Diabetic Retinopathy Study letters was used as the outcome variable in univariate and multivariate analysis testing the measured SD OCT variables as predictors. RESULTS: A statistically significant correlation between percentage disruption of the IS/OS junction and visual acuity was found (P = .0312). Additionally, there was a strong trend suggesting a relationship between macular volume and visual acuity, although borderline significance was found (P = .07). CONCLUSIONS: Disruption of the photoreceptor IS/OS junction is an important predictor of visual acuity among diabetic macular edema patients.
目的:使用频域光相干断层扫描(SD OCT)评估糖尿病性黄斑水肿患者的光感受器内节/外节(IS/OS)连接的完整性,并分析 IS/OS 连接完整性与视力之间的关系。
设计:回顾性、对比、连续病例系列。
方法:对 38 例糖尿病性黄斑水肿患者的 62 只眼进行 SD OCT 成像。对于每个患者,2 名经验丰富的观察者在不了解视力测量结果的情况下,对中央黄斑厚度、视网膜容积、外视网膜整体破坏程度、外视网膜破坏百分比和先前治疗史等多个 SD OCT 变量进行了测量。将记录的视力(以早期糖尿病视网膜病变研究字母数表示)作为因变量,在单变量和多变量分析中,测试 SD OCT 变量作为预测因子。
结果:IS/OS 连接破坏百分比与视力之间存在统计学显著相关性(P =.0312)。此外,尽管存在边缘显著意义(P =.07),但黄斑容积与视力之间存在强烈的趋势关系。
结论:光感受器 IS/OS 连接的破坏是糖尿病性黄斑水肿患者视力的重要预测因子。
Graefes Arch Clin Exp Ophthalmol. 2012-2-23
Graefes Arch Clin Exp Ophthalmol. 2009-10
Graefes Arch Clin Exp Ophthalmol. 2016-3
Invest Ophthalmol Vis Sci. 2013-2-7
Pharmaceutics. 2025-5-2
Indian J Ophthalmol. 2025-1-1
Eye (Lond). 2025-2
Ophthalmologie. 2024-8
Graefes Arch Clin Exp Ophthalmol. 2009-10
Invest Ophthalmol Vis Sci. 2005-9